ADC Therapeutics
ADCT
58 hedge funds and large institutions have $274M invested in ADC Therapeutics in 2022 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 15 increasing their positions, 9 reducing their positions, and 4 closing their positions.
275% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 4
69% more call options, than puts
Call options by funds: $198K | Put options by funds: $117K
67% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 9
18% more funds holding
Funds holding: 49 → 58 (+9)
0.46% more ownership
Funds ownership: 44.43% → 44.88% (+0.46%)
45% less capital invested
Capital invested by funds: $501M → $274M (-$227M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
+$6.06M |
| 2 |
BlackRock
New York
|
+$1.54M |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
+$1.32M |
| 4 |
Morgan Stanley
New York
|
+$1.13M |
| 5 |
Principal Financial Group
Des Moines,
Iowa
|
+$954K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$4.74M |
| 2 |
VCG
Vantage Consulting Group
Virginia Beach,
Virginia
|
-$4.67M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$899K |
| 4 |
AA
ALPS Advisors
Denver,
Colorado
|
-$315K |
| 5 |
VEA
Virtus ETF Advisers
New York
|
-$282K |
ADCT Hedge Fund Activity: Q2 2022 in Review
58 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in ADC Therapeutics (ADCT) for Q2 2022, worth a combined $274M — down 45% from $501M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new ADCT positions and 4 closed out — a net gain of 11 holders — while 15 added to existing stakes and 9 trimmed.
The largest buyer was Walleye Capital, adding an estimated $6.06M. The largest seller was T. Rowe Price Associates, cutting an estimated $4.74M.
- 58 institutional investors held ADC Therapeutics (ADCT) as of Q2 2022, up from 49 in Q1 2022.
- Funds reported $274M of ADC Therapeutics stock for Q2 2022, down 45% quarter-over-quarter.
- 15 funds opened new ADC Therapeutics positions in Q2 2022 and 4 closed out, a net change of +11 holders.
- The largest ADC Therapeutics buyer in Q2 2022 was Walleye Capital, an estimated $6.06M added.
- The largest ADC Therapeutics seller in Q2 2022 was T. Rowe Price Associates, an estimated $4.74M sold.
Based on aggregated 13F filings for Q2 2022.